Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Briefs: Indoco Remedies and Alembic Pharmaceuticals

Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe

India reiterates commitment to adolescents on launch of ‘Economic Case for Investment in the Well-being of Adolescents in India’ report

Report highlights significant improvements in adolescent well-being in India

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting

Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr

Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024

Max Healthcare CMD Abhay Soi recognised as one of the highest individual tax payers in India

Abhay Soi, who had paid an income tax of approximately Rs 400 crore in the assessment year 2023-24 has been recognised as the “Top Individual tax payers having gross tax payable > Rs 10 Lakhs"

Emcure Pharmaceuticals signs PPA with Sunsure Energy for solar power

The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants

Mankind Pharma to acquire 100% stake in Bharat Serums from Advent for Rs. 13,630 Cr

Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands

Pfizer announces positive topline results from Phase 3 study of hemophilia A gene therapy candidate

Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis

European Commission approves Pfizer’s Durveqtix gene therapy for adults with hemophilia B

A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)